Get started
Denali Therapeutics Inc.Denali Therapeutics Inc.Denali Therapeutics Inc.

Denali Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

DNLI chart


Full chart

DNLI upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.87 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.85USD
Net income (FY)
‪−145.22 M‬USD
Revenue (FY)
‪330.53 M‬USD
Shares float
‪119.11 M‬
Beta (1Y)
2.40

Employees


Employees (FY)
445
Change (1Y)
+18 +4.22%
Revenue / Employee (1Y)
‪742.77 K‬USD
Net income / Employee (1Y)
‪−326.35 K‬USD

About Denali Therapeutics Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Ryan J. Watts
Website
denalitherapeutics.com
Headquarters
San Francisco
Founded
2013
FIGI
BBG008P7F869
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

DNLI news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of DNLI is 27.05 USD — it has increased by 4.20% in the past 24 hours. Watch Denali Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Denali Therapeutics Inc. stocks are traded under the ticker DNLI.
DNLI stock has risen by 1.92% compared to the previous week, the month change is a −4.65% fall, over the last year Denali Therapeutics Inc. has showed a 40.01% increase.
We've gathered analysts' opinions on Denali Therapeutics Inc. future price: according to them, DNLI price has a max estimate of 90.00 USD and a min estimate of 22.00 USD. Watch DNLI chart and read a more detailed Denali Therapeutics Inc. stock forecast: see what analysts think of Denali Therapeutics Inc. and suggest that you do with its stocks.
DNLI reached its all-time high on Dec 22, 2020 with the price of 93.94 USD, and its all-time low was 12.32 USD and was reached on Jul 31, 2018. View more price dynamics on DNLI chart.
See other stocks reaching their highest and lowest prices.
DNLI stock is 5.82% volatile and has beta coefficient of 2.40. Track Denali Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Denali Therapeutics Inc. there?
Today Denali Therapeutics Inc. has the market capitalization of ‪3.72 B‬, it has increased by 1.55% over the last week.
Yes, you can track Denali Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Denali Therapeutics Inc. is going to release the next earnings report on Nov 4, 2024. Keep track of upcoming events with our Earnings Calendar.
DNLI earnings for the last quarter are −0.59 USD per share, whereas the estimation was −0.70 USD resulting in a 16.01% surprise. The estimated earnings for the next quarter are −0.60 USD per share. See more details about Denali Therapeutics Inc. earnings.
Denali Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪10.00 M‬ USD. In the next quarter, revenue is expected to reach ‪6.30 M‬ USD.
DNLI net income for the last quarter is ‪−99.03 M‬ USD, while the quarter before that showed ‪−101.80 M‬ USD of net income which accounts for 2.73% change. Track more Denali Therapeutics Inc. financial stats to get the full picture.
No, DNLI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 2, 2024, the company has 445.00 employees. See our rating of the largest employees — is Denali Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Denali Therapeutics Inc. EBITDA is ‪−486.71 M‬ USD, and current EBITDA margin is −54.45%. See more stats in Denali Therapeutics Inc. financial statements.
Like other stocks, DNLI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Denali Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Denali Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Denali Therapeutics Inc. stock shows the buy signal. See more of Denali Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.